Navigation Links
Commercial future for Model Gut
Date:2/26/2013

The Dynamic Gastric Model, developed from years of research at the Institute of Food Research, has taken significant steps towards improving its commercial use by food and drug companies worldwide.

IFR and the technology management company Plant Bioscience Limited (PBL) have secured funding from the Biotechnology and Biological Sciences Research Council (BBSRC) to further develop the Dynamic Gastric Model to validate and improve how well it simulates the release of nutrients or drugs in humans.

PBL has also signed an exclusive license agreement with Bioneer regarding use of the Dynamic Gastric Model (DGM). Bioneer has also acquired PBL's highly successful DGM contract research business (www.modelgut.com) which provides specialist DGM services to the pharmaceutical and food-related industries.

The DGM is based on 15 years of research at the Institute of Food Research, in partnership with PBL. It accurately simulates the physical and biochemical processes that occur within the human stomach. It is the world's first computer controlled, mechanical simulator of gastric digestion that works in real-time to process real chewed foods or meals and oral pharmaceutical or nutraceutical products.

The commercialisation of the model represents a significant achievement for IFR in developing research and making it commercially viable. It is an example of IFR's commitment to the translation of our science for the benefit of society and commerce.

IFR will continue to work with the DGM, as part of its core research into understanding the complex interaction between health, the food we eat and our gut. The new two-year project, with funding from the BBSRC's Super Follow on Fund scheme, is worth over 900k and will refine and improve models to ensure that IFR can continue its strategic research to determine how the nutritional quality and health benefits of the food we eat can be influenced by the way it is digested. This research at IFR in the future will continue to utilise the in vitro models which have been developed here including the DGM and the model colon.

The model will also be further developed to enable studies that would not be permitted in humans; for instance, the impact of taking drugs with alcohol, or the development of an infant formulation.

IFR's Professor Peter Wilde said: "We will clearly demonstrate how well the model simulates and predicts the availability of nutrients or drugs in humans, and to refine the model so that it can be more widely used, and therefore reduce the reliance on animal and human studies. This will significantly enhance the commercial and scientific potential of the model."

The license agreement for the Dynamic Gastric Model expands Bioneer's readily available services for pharmaceutical dosage form testing, drug discovery screening, bioequivalence assessment, and functional food analysis. The Model Gut services will be integrated into Bioneer's own service offering under the Bioneer:FARMA brand.

Professor Anette Mllertz, Head of Department at Bioneer:FARMA said: "The DGM takes our services to a highly advanced level. In combination with our existing digestion models, we can now conduct advanced analyses along the whole gastro-intestinal tract."

Martin Stocks, PBL Business Development Manager, said: "We are delighted to partner Bioneer:FARMA to take The Model Gut into an exciting new phase. The integration with Bioneer:FARMA will provide a wide array of complementary capabilities that will both expand and enable the unique capabilities of the Model Gut's technologies for determining the performance of ingested materials in the gastric and intestinal compartments."


'/>"/>

Contact: Andrew Chapple
andrew.chapple@ifr.ac.uk
44-016-032-51490
Norwich BioScience Institutes
Source:Eurekalert  

Related biology news :

1. Kessler Foundation implements Ekso Bionics first commercial robotic exoskeleton
2. A study confirms that long commercials evoke stronger emotions
3. Researchers take hibiscus efforts to commercialization
4. Sandia seeks commercial partners for revolutionary SpinDx medical diagnostic tool
5. NIST focuses on testing standards to support lab on a chip commercialization
6. Bed bugs are not repelled by commercial ultrasonic frequency devices
7. UC Berkeley, UCSF and Stanford join forces to help commercialize university innovations
8. The future of plant science - a technology perspective
9. The future of plant science a technology perspective
10. Is seaweed the future of biofuel?
11. Algae biofuels: the wave of the future
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Commercial future for Model Gut
(Date:6/20/2016)... , June 20, 2016 Securus Technologies, ... technology solutions for public safety, investigation, corrections and ... prisons involved, it has secured the final acceptance ... facilities for Managed Access Systems (MAS) installed. Furthermore, ... facilities to be installed by October, 2016. MAS ...
(Date:6/9/2016)... ISTANBUL , June 9, 2016  Perkotek an innovation leader in attendance control ... to seamlessly log work hours, for employers to make sure the right employees are ... Logo - http://photos.prnewswire.com/prnh/20160609/377486LOGO ... ... ...
(Date:6/3/2016)... , June 3, 2016 ... Management) von Nepal ... und Lieferung hochsicherer geprägter Kennzeichen, einschließlich Personalisierung, ... führend in der Produktion und Implementierung von ... der Ausschreibung im Januar teilgenommen, aber Decatur ...
Breaking Biology News(10 mins):
(Date:6/27/2016)... , June 27, 2016  Global demand for ... percent through 2020 to $7.2 billion.  This market ... beverages, cleaning products, biofuel production, animal feed, and ... diagnostics, and biocatalysts). Food and beverages will remain ... by increasing consumption of products containing enzymes in ...
(Date:6/27/2016)... ... 2016 , ... Newly created 4Sight Medical Solutions ... healthcare market. The company's primary focus is on new product introductions, to include ... are necessary to help companies efficiently bring their products to market. , The ...
(Date:6/24/2016)... 2016 Epic Sciences unveiled a liquid ... to PARP inhibitors by targeting homologous recombination deficiency ... new test has already been incorporated into numerous ... types. Over 230 clinical trials are ... including PARP, ATM, ATR, DNA-PK and WEE-1. Drugs ...
(Date:6/23/2016)... 2016   Boston Biomedical , an industry ... to target cancer stemness pathways, announced that its ... Drug Designation from the U.S. Food and Drug ... including gastroesophageal junction (GEJ) cancer. Napabucasin is an ... cancer stemness pathways by targeting STAT3, and is ...
Breaking Biology Technology: